IndustryCompany release

Theriva Sells SYN-004 Antibiotic-Enzyme Assets to Biossil Labs for $350,000 Upfront

🇺🇸 Theriva Biologics, Inc. (TOVX) · Thu 12 Nov 2026

The US biotech reported third-quarter results alongside the divestment, and said VIRAGE2 enrolment in metastatic pancreatic cancer should finish in the fourth quarter of 2026.

Theriva Biologics has sold SYN-004 (ribaxamase) and related antibiotic-degrading enzyme assets to Biossil Labs. The company announced the deal on 12 November 2026 together with its third-quarter results.

Under the terms reported, Theriva receives $350,000 upfront. It is also eligible for up to $91 million in milestone payments, plus royalties.

On its clinical pipeline, Theriva expects to complete enrolment in VIRAGE2 in the fourth quarter of 2026. The trial is a Phase 2a study of VCN-01 in metastatic pancreatic cancer, with initial data expected by the third quarter of 2027.

The company also expects further discussions with the US Food and Drug Administration (FDA) in the first quarter of 2027 about a trial in retinoblastoma. No other details of those talks were given.

Theriva held $8.5 million in cash at 30 September 2026. It said this is enough to fund operations into the first quarter of 2027.

What it means for your team

  • Teams tracking antibiotic-resistance and microbiome-protection approaches should note that SYN-004 and related enzyme assets now sit with Biossil Labs rather than Theriva.
  • The small upfront payment against up to $91 million in milestones means most of the deal's value depends on future development and commercial events.
  • VIRAGE2 enrolment completion is expected in Q4 2026, with initial data by Q3 2027; the FDA retinoblastoma discussions are slated for Q1 2027.
  • Cash runway into Q1 2027 puts financing and partnering questions close to the pipeline milestones.

Company's press release (SEC filing): Theriva Biologics, Inc. ↗

Article written by VigiEye from the official source (Theriva Biologics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →